CommercialPrior AuthHigh impact
Immunoglobulin Therapy
Blue Cross & Blue Shield of Mississippi·MS · Hematology, Oncology, Rheumatology +4 more·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBSMS updated their immunoglobulin therapy policy requiring prior authorization for all IVIG and SCIG treatments. Several immunoglobulin products are now non-formulary and not covered, while specific formulary agents (Gammagard Liquid, Gammaked, Gamunex-C, Octagam, Privigen for IV; Cutaquig, Hizentra, Xembify for subcutaneous) require meeting detailed medical necessity criteria.
Action Required
Immediately: Billing team must implement prior authorization requirements for all immunoglobulin therapy claims (IVIG and SCIG). Update billing system to flag these services for prior auth. Providers must verify patient's specific BCBSMS formulary coverage before prescribing and ensure detailed documentation of medical necessity criteria is met. Claims for non-formulary products (Alyglo, Asceniv, Bivigam, Cuvitru, Flebogamma DIF, Gammagard S/D, Gammaplex, GamaSTAN, Hyqvia, Panzyga, Yimmugo) will be denied.